Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 2/20 | 0.50 |
| ▸ | HTR6 | P50406 | 5/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2183807 | 1.00 | F10 (0.50) | F10HTR6MAOAMAOBGRM2 | |
| SCHEMBL2184137 | 0.88 | MAOA (0.55) | HTR6MAOAMAOBGRM2 | |
| SCHEMBL2184129 | 0.88 | MAOA (0.55) | HTR6MAOAMAOBGRM2 | |
| SCHEMBL9447681 | 0.85 | F10 (0.53) | F10HTR6MAOAMAOBGRM2 | |
| SCHEMBL9447636 | 0.85 | F10 (0.53) | F10HTR6MAOAMAOBGRM2 | |
| SCHEMBL6191925 | 0.84 | F10 (0.55) | F10HTR6MAOAMAOBGRM2 | |
| SCHEMBL3718329 | 0.83 | HTR6 (0.46) | F10HTR6MAOAMAOB | |
| SCHEMBL2184784 | 0.83 | GRM2 (0.41) | F10HTR6MAOAMAOBGRM2 | |
| SCHEMBL3718323 | 0.82 | HTR6 (0.45) | F10HTR6MAOAMAOB | |
| SCHEMBL14334740 | 0.79 | NR1H2 (0.49) | F10MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8741890-B2 | Substituted amides, manufacturing and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-03 | — | — | US | disclosed |
| US-20110166125-A1 | SUBSTITUTED AMIDES, MANUFACTURING AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
| EP-2220079-A2 | SUBSTITUTED AMIDES, MANUFACTURING AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009063028-A2 | SUBSTITUTED AMIDES, MANUFACTURING AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166125-A1 | SUBSTITUTED AMIDES, MANUFACTURING AND USE THEREOF AS MEDICAMENTS | ARG1, P4HA1, ASS1 | F10 981/4885HTR6 3859/4885MAOA 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.